BioNxt
-
BioNxt Initiates 15-Day Sublingual Cladribine Optimization Study for Bioequivalence Trial
BioNxt (BNXTF) has initiated a large-mass animal study for BNT23001, a sublingual cladribine film for multiple sclerosis, to optimize dosing before human trials planned for early 2026. The study, expected to complete in November 2025 with results in December 2025, aims to improve bioavailability and simplify dosing. Patent nationalization is ongoing, with positive notices from European and Eurasian Patent Offices, and a priority filing in the US. BNT23001 targets improved outcomes for dysphagia patients, offering a non-tablet option.
